Lenvatinib Slows Resistant Thyroid Ca

June 1, 2014 4:01 AM

17 0

CHICAGO -- The targeted agent lenvatinib extended progression-free survival (PFS) among patients with treatment-refractory thyroid cancer, researchers said here.

Patients who received lenvatinib had a median PFS of 18.3 months compared with patients on placebo who had a PFS of 3.6 months -- a significant 14.7-month difference (P<0.0001), reported Martin Schlumberger, MD, of the University Paris Sud, and colleagues.

Read more

To category page